Zealand Pharma reported that the PK profile of their long-acting GLP-2 analog, glepaglutide, supports once-or twice-weekly dosing based on initial results from a Phase 1 trial in 75 healthy subjects. Different daily and weekly subcutaneous doses of glepaglutide were evaluated in the trial and the results suggest that twice- and potentially once-weekly dosing with glepaglutide will provide adequate exposure for clinical effect. Both a once- and twice-weekly dosing regimen is proposed for Phase 3 and the trial is expected to enroll between 120 and 150 patients. Meetings with U.S. and EU regulatory authorities to agree on the final trial design are planned with the aim of commencing Phase 3 clinical trials in 2018.